Kingsview Wealth Management LLC Sells 4,803 Shares of Johnson & Johnson $JNJ

Key Points

• Kingsview Wealth Management reduced its Johnson & Johnson stake by 4.9%, selling 4,803 shares and retaining 94,143 shares valued at approximately $23.9 million. Institutional investors still own about 69.55% of JNJ.
• Analysts remain broadly positive, with JNJ carrying a “Moderate Buy” consensus rating and an average price target of $272.83; several firms recently raised their targets, including UBS with a $320 objective.
• Johnson & Johnson reported quarterly EPS and revenue above expectations, with revenue up 6.6% year over year, and reaffirmed 2026 EPS guidance of $11.60–$11.75. The company also pays a quarterly dividend of $1.34 per share, yielding about 2.0% annually.

Kingsview Wealth Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 94,143 shares of the company's stock after selling 4,803 shares during the period. Kingsview Wealth Management LLC's holdings in Johnson & Johnson were worth $23,909,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of JNJ. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in Johnson & Johnson by 4.9% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 222,206 shares of the company's stock valued at $56,431,000 after buying an additional 10,400 shares during the period. Rakuten Investment Management Inc. boosted its position in Johnson & Johnson by 10.1% during the 2nd quarter. Rakuten Investment Management Inc. now owns 393,806 shares of the company's stock valued at $101,803,000 after acquiring an additional 36,182 shares in the last quarter. RB Capital Management LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the 2nd quarter. RB Capital Management LLC now owns 10,243 shares of the company's stock valued at $2,601,000 after acquiring an additional 128 shares during the period. Maxele Advisors LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $427,000. Finally, Empowered Funds LLC raised its position in shares of Johnson & Johnson by 11.7% in the 2nd quarter. Empowered Funds LLC now owns 348,850 shares of the company's stock worth $88,597,000 after acquiring an additional 36,477 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer called the pullback a buying opportunity, citing Johnson & Johnson’s defensive characteristics and long-term stability. The commentary may support investor interest, but it is opinion-based rather than a new company catalyst. Cramer says it is time to buy the dip on JNJ
• Positive Sentiment: Johnson & Johnson announced that 24 abstracts will be presented at Psych Congress 2026, including the first pivotal Phase 3 CAPLYTA data in adults with bipolar mania, along with new SPRAVATO analyses and schizophrenia research. The updates could strengthen confidence in the company’s neuropsychiatry pipeline and future pharmaceutical growth. Johnson & Johnson neuropsychiatry data announcement
• Neutral Sentiment: Investors are watching defensive stocks such as JNJ ahead of upcoming CPI data and the Federal Reserve’s rate decision. The company’s dividend and healthcare exposure may provide stability, but interest-rate and macroeconomic uncertainty are driving near-term volatility. Defensive stocks to watch as CPI and the Fed test the rally
• Neutral Sentiment: A comparison with Eli Lilly frames JNJ as the steadier, more established investment, but with less breakout-growth potential. The article highlights the trade-off between JNJ’s stability and pharmaceutical-industry growth opportunities. Lilly versus J&J investment comparison
• Negative Sentiment: An executive sold approximately $9.23 million of JNJ stock. While insider selling does not necessarily indicate weakening fundamentals, the transaction can create a modest sentiment overhang. Johnson & Johnson executive stock sale

Analysts Set New Price Targets

Several equities analysts have issued reports on JNJ shares. Citigroup lifted their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. UBS Group started coverage on shares of Johnson & Johnson in a research note on Wednesday, September 2nd. They set a "buy" rating and a $320.00 price objective for the company. Bank of America raised their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research note on Friday, July 10th. TD Cowen upped their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Finally, Guggenheim boosted their target price on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $272.83.

Insiders Place Their Bets

In other news, EVP Kathryn Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 97,569 shares of company stock valued at $25,476,044. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 2.3%

Shares of Johnson & Johnson stock opened at $269.04 on Wednesday. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07. The stock has a market cap of $648.35 billion, a P/E ratio of 31.17, a P/E/G ratio of 2.63 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock's 50 day simple moving average is $262.61 and its 200-day simple moving average is $245.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's dividend payout ratio is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.